Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Amedica Announces Pricing of $11 Million Public Offering
-
Onconova Reminds Shareholders That Rights Offering Ownership Day is Friday, July 1, 2016
-
Stellar Biotechnologies (SBOT) Prices $6.75M Registered Direct Offering
-
Stellar Biotechnologies Announces Pricing of $6.75 Million Registered Direct Offering
-
Capnia Announces Private Placement of Up to $13.8 Million of Convertible Preferred Stock
-
Onconova Announces Price Range and Change of Key Dates for Rights Offering
-
Maxim Group Downgrades Suffolk Bancorp (SCNB) to Hold
-
Regenerx Biopharma (RGRX) Announces 5.15M Share Private Stock Placement
-
RegeneRx Announces $1.75 Million Private Placement
-
Notable Analyst Rating Changes 6/23: (POST) (HD) (MU) Upgraded; (SJM) (TSLA) (CACI) Downgraded
-
Maxim Group Starts eBay (EBAY) at Buy
-
Maxim Group Starts Groupon, Inc. (GRPN) at Buy
-
Maxim Group Starts Amazon.com (AMZN) at Buy
-
Streetinsider.com's Hot Lunchtime Reads 6/20: (GPRO) (SQ) (INO) (MSFT)
-
Maxim Group Reiterates Bullish View on Inovio (INO) as Zika Vaccine Gets Green Light For Human Study
-
Onconova Informs Stockholders of Key Dates Related to Announced Rights Offering
-
Viveve(R) Announces Closing of $15.5 Million Underwritten Public Offering
-
Oculus Innovative Sciences (OCLS): Building a Commercial Presence - Maxim Group
-
Seaspan Announces Closing of $115 Million Public Offering of 8.20% Series G Cumulative Redeemable Perpetual Preferred Shares
-
Soligenix Develops Defenses Against Bioterrorism
-
Cytori Closes Rights Offering for Gross Proceeds of $17.1 Million
-
Immune Therapeutics, Inc. Announces Engagement of Maxim Group LLC to Provide Strategic Advisory Services
-
Propanc Identifies Future Opportunities for PRP as Pharma Executives Look for New Breakthroughs
-
Viveve Medical (VIVE) Prices 2.7M Shares at $5 in NASDAQ Uplisting
-
Viveve(R) Announces Pricing of $13.5 Million Public Offering of Shares of Common Stock and NASDAQ Uplisting
-
Maxim Group Starts SITO Mobile (SITO) at Buy
-
Cytori Announces Expiration of Rights Offering and Estimated Gross Proceeds of $17.1 Million
-
Seaspan Announces Pricing of $100 Million Public Offering of 8.2% Series G Cumulative Redeemable Perpetual Preferred Shares
-
Mast Theraputics (MSTX): Building IP to Treat Sickle Cell Pain Crisis - Maxim Group
-
Seaspan Announces Public Offering of Series G Cumulative Redeemable Perpetual Preferred Shares
-
Maxim Group Starts Workhorse Group (WKHS) at Buy
-
Maxim Group Starts Landec (LNDC) at Buy
-
Joseph Gunnar & Co., LLC is pleased to announce the hiring of Ashok Kumar to Head its Equity Research Department
-
Cytori Extends Rights Offering Subscription Period to Friday, June 10, and Adjusts Unit Pricing
-
Maxim Positive on BrainStorm Cell Therapeutics (BCLI) into Upcoming NurOwn Phase 2 Data in ALS; Affirms at 'Buy'
-
Notable Analyst Rating Changes 6/3: (UNP) (DE) (WFT) Upgraded; (ICLR) (TSL) (PCAR) Downgraded
-
Maxim Group Starts Yelp (YELP) at Buy
-
Maxim Group Starts GrubHub Inc. (GRUB) at Buy
-
Maxim Group Upgrades EnerSys (ENS) to Buy
-
Onconova Files S-1 Registration Statement for Rights Offering to Shareholders
-
Maxim Group Says Galena Biopharma (GALE) Fast Track is Positive and Further Validates NeuVax Potential
-
Maxim Group Downgrades StemCells (STEM) to Hold
-
ContraVir Pharma (CTRV) Gains Key Preclinical Antiviral Asset with Ciclofilin Pharna Deal; Maxim Affirms at 'Buy'
-
Propanc Engages Two Advisory Firms to Identify Strategic Partnering Opportunities
-
Cytori Announces Commencement of Subscription Period for Previously Announced Rights Offering
-
Reed's (REED) Enters $2.2M Common Stock, Warrants Private Placement
-
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
-
Reed’s Announces $2.2 Million Private Placement
-
OncoSec Closes $10 Million At-The-Market Registered Direct Offering
-
Notable Analyst Rating Changes 5/26: (ADM) (INFY) (SKIS) Upgraded; (HBAN) (NWN) (USDP) Downgraded

